Use of hepatitis B surface and 'e' antigen quantification during extensive treatment with tenofovir in patients co-infected with HIV-HBV

摘要

Background & AimsIn patients infected with hepatitis B virus (HBV) and HIV, hepatitis B e' antigen (qHBeAg) and hepatitis B surface antigen quantification (qHBsAg) may be used to predict short-term HBeAg and HBsAg loss, respectively. To determine if these quantifiable markers also provide accurate prediction of antigen loss during long-term, extensive tenofovir (TDF) treatment and to further establish qHBsAg profiles associated with HBsAg seroconversion.